RBC Capital Comments on BioMarin (BMRN) Following Prosensa (RNA) Deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/30/2026
- US stock futures tick up as strong quarter nears end
- Strong dollar pushes yen to 40-year low as traders test Japanese authorities
- Citi says bearish flows are building in Nasdaq and S&P 500
- Patrick and LCI Industries to merge in all-stock deal
- Comcast shares surge 23% on blockbuster plan to spin off NBCUniversal and Sky
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- EchoStar Prepares Dish DBS Bankruptcy Filing as Soon as Tuesday - WSJ
- Strategy stock jumps 7% as firm shifts to active capital management
- New leader board: Citi refreshes AI compute semiconductor picks
- Honeywell completes aerospace spin-off, splits into 3 companies
BioMarin Pharma (BMRN) to Acquire Prosensa (RNA) for $17.75/Share
November 24, 2014 6:01 AM ESTBioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Prosensa Holding N.V. (Nasdaq: RNA) announced that they have entered into a definitive agreement in which BioMarin will offer to purchase all of the outstanding ordinary shares of Prosensa for $17.75 per share, for a total up front consideration of approximately $680 million. In addition, two approximately $80 million contingent milestones are payable for the approval of drisapersen in the U.S. no later than May 15, 2016 and Europe no later than February 15, 2017, respectively.
"BioMarin is dedicated to the rare disease community, and the acquisition... More
